FisclearFisclear

Financial Comparison

Cipla Limited vs Sun Pharmaceutical Industries Limited

Click a ticker to view the full analysis.

CIPLA.NS vs

In short

Sun Pharmaceutical Industries Limited is the more profitable of the two, keeping 19.7% of revenue as net profit against 14.0% for Cipla Limited. Sun Pharmaceutical Industries Limited trades at the higher trailing P/E (35.2× vs 31.9× for Cipla Limited), so investors pay more for each dollar of its earnings. Fisclear flags 0 medium- or high-severity risks for Cipla Limited and 0 for Sun Pharmaceutical Industries Limited.

Based on filings for periods ending 31 Mar 2026 (CIPLA.NS) and 31 Mar 2026 (SUNPHARMA.NS) · Updated

FisclearScore Comparison

CIPLA.NS51Fair
SUNPHARMA.NS68Strong
Quality+5
89
94
Efficiency+15
47
62
Value+36
26
62
Cashflow+31
25
56
Regime
55
55
Peers+12
58
70

FisclearScore is a quantitative model. CIPLA.NS shown solid · SUNPHARMA.NS shown dashed. Not financial advice.

MetricCIPLA.NSSUNPHARMA.NS
Price₹1,310.50₹1,772.00
Market Cap₹1.06T₹4.25T
P/E (TTM)31.9x35.2x
P/B3.1x5.1x
Beta0.090.14
Div Yield0.99%0.91%
Revenue (TTM)₹277.1B₹582.2B
Net Income₹38.8B₹114.8B
Gross Margin62.3%77.4%
Risk Flags——
Full CIPLA.NS Report →Full SUNPHARMA.NS Report →

Related comparisons

Dr. Reddy's Laboratories vs Sun PharmaceuticalDIVISLAB.NS vs Sun PharmaceuticalAPOLLOHOSP.NS vs Sun PharmaceuticalSun Pharmaceutical vs TORNTPHARM.NSCIPLA.NS vs Dr. Reddy's LaboratoriesCIPLA.NS vs DIVISLAB.NS

Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.